Amit  Rakhit net worth and biography

Amit Rakhit Biography and Net Worth

Amit Rakhit, MD, is Chief Executive Officer at Sporos, a privately held biotech company with four subsidiary companies and internal biodiscovery that aims to catalyze the rapid development of breakthrough therapies that target novel disease mechanisms in cancer, fibrosis, inflammation, and immune-related diseases.

Prior to his leadership of Sporos Bioventures, Dr. Rakhit was president and Chief Medical Officer of Ovid Therapeutics, a publicly traded biotechnology company focused on developing medicines for people living with rare neurologic conditions. Rakhit oversaw the drug development and commercialization path for investigational compounds in the Ovid portfolio. He is a senior healthcare executive with more than 20 years’ experience including both clinical practice and pharmaceutical/biotechnology industry experience. Rakhit earned his Bachelor of Arts in molecular biology from the University of California, Berkeley, his MD from Tufts University School of Medicine, his Master of Science from Vanderbilt University School of Medicine, and dual MBAs from the London Business School and Columbia University. He completed his fellowship in pediatric cardiology and was subsequently on staff at The Children’s Hospital, Boston affiliated with Harvard University.

Prior to Ovid, Rakhit was SVP and Head of Worldwide Medical at Biogen, where he led the medical function for marketed and pipeline compounds in disease areas such as multiple sclerosis, neurodegenerative diseases, hemophilia, spinal muscular atrophy, and amyotrophic lateral sclerosis. Prior to Biogen, Rakhit led an international region at Bristol-Myers Squibb with a cross-therapeutic area portfolio including cardiovascular, metabolics, oncology, HIV, virology, immunology, and neuroscience products.

Rakhit is an advisory member of the Healthcare Board of the Partnership Fund for New York City. He worked with Mother Teresa at the Missionaries of Charity (Kolkata). Rakhit also supports the Human Rights Campaign, and is a co-founder of KoMocean swimwear. He lives with his partner in NYC.

How do I contact Amit Rakhit?

The corporate mailing address for Dr. Rakhit and other Ovid Therapeutics executives is 1460 Broadway Suite 15044, New York NY, 10036. Ovid Therapeutics can also be reached via phone at (646) 661-7661 and via email at [email protected]. Learn More on Amit Rakhit's contact information.

Has Amit Rakhit been buying or selling shares of Ovid Therapeutics?

Amit Rakhit has not been actively trading shares of Ovid Therapeutics in the last ninety days. Most recently, Amit Rakhit sold 34,017 shares of the business's stock in a transaction on Wednesday, July 14th. The shares were sold at an average price of $3.71, for a transaction totalling $126,203.07. Learn More on Amit Rakhit's trading history.

Are insiders buying or selling shares of Ovid Therapeutics?

During the last year, Ovid Therapeutics insiders bought shares 1 times. They purchased a total of 18,248 shares worth more than $50,364.48. The most recent insider tranaction occured on March, 18th when CEO Jeremy M Levin bought 18,248 shares worth more than $50,364.48. Insiders at Ovid Therapeutics own 12.6% of the company. Learn More about insider trades at Ovid Therapeutics.

Information on this page was last updated on 3/18/2024.

Amit Rakhit Insider Trading History at Ovid Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/14/2021Sell34,017$3.71$126,203.07View SEC Filing Icon  
See Full Table

Amit Rakhit Buying and Selling Activity at Ovid Therapeutics

This chart shows Amit Rakhit's buying and selling at Ovid Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ovid Therapeutics Company Overview

Ovid Therapeutics logo
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Read More

Today's Range

Now: $2.99
Low: $2.99
High: $3.14

50 Day Range

MA: $3.20
Low: $2.72
High: $3.84

2 Week Range

Now: $2.99
Low: $2.57
High: $4.14

Volume

112,117 shs

Average Volume

194,150 shs

Market Capitalization

$211.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71